Is the Neutrophil-Lymphocyte Ratio an Indicator of Progression in Patients with Benign Prostatic Hyperplasia? |
Tanik, Serhat
(Department of Urology, Bozok University, School of Medicine)
Albayrak, Sebahattin (Department of Urology, Bozok University, School of Medicine) Zengin, Kursad (Department of Urology, Bozok University, School of Medicine) Borekci, Hasan (Department of General Surgery, Bozok University, School of Medicine) Bakirtas, Hasan (Department of Urology, Bozok University, School of Medicine) Imamoglu, M. Abdurrahim (Department of Urology, Bozok University, School of Medicine) Gurdal, Mesut (Department of Urology, Bozok University, School of Medicine) |
1 | Araki T, Monden K, Araki M (2013). Comparison of 7 alpha(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia:a short-term crossover study. Acta Med Okayama, 67, 245-51. |
2 | Celikbilek M, Dogan S, Ozbakir O, et al (2013). Neutrophillymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal, 27, 72-6. DOI |
3 | Crawford ED, Wilson SS, McConnell JD, et al (2006). Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol, 175, 1422-6; discussion 6-7. DOI |
4 | De Marzo AM, Platz EA, Sutcliffe S, et al (2007). Inflammation in prostate carcinogenesis. Nat Rev Cancer, 7, 256-69. DOI ScienceOn |
5 | De Nunzio C, Kramer G, Marberger M, et al (2011). The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol, 60, 106-17. DOI ScienceOn |
6 | Di Silverio F, Gentile V, De Matteis A, et al (2003). Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol, 43, 164-75. DOI ScienceOn |
7 | Djavan B, Eckersberger E, Espinosa G, et al (2009). Complex mechanisms in prostatic inflammatory response. Eur Urology Supplements, 8, 872-8. DOI |
8 | Emberton M, Fitzpatrick JM, Rees J (2011). Risk stratification for benign prostatic hyperplasia (BPH) treatment. BJU Int, 107, 876-80. DOI |
9 | Falahatkar S, Mokhtari G, Pourreza F, et al (2008). Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology, 72, 813-6. DOI |
10 | Fibbi B, Penna G, Morelli A, et al (2010). Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl, 33, 475-88. |
11 | Halazun KJ, Hardy MA, Rana AA, et al (2009). Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg, 250, 141-51. DOI ScienceOn |
12 | Izmirli M, Arikan B, Bayazit Y, et al (2011). Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men. Asian Pac J Cancer Prev, 12, 731-3. |
13 | Kandirali E, Boran C, Serin E, et al (2007). Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Urology, 70, 743-7. DOI |
14 | Karaman H, Karaman A, Erden A, et al (2013). Relationship between colonic polyp type and the neutrophil/ lymphocyte ratio as a biomarker. Asian Pac J Cancer Prev, 14, 3159-61. 과학기술학회마을 DOI ScienceOn |
15 | Karazanashvili G (2008). Editorial comment on: the relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol, 54, 1383-4. DOI |
16 | Konwar R, Manchanda PK, Chaudhary P, et al (2010). Glutathione S-transferase (GST) gene variants and risk of benign prostatic hyperplasia: a report in a North Indian population. Asian Pac J Cancer Prev, 11, 1067-72. |
17 | Mishra VC, Allen DJ, Nicolaou C, et al (2007). Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int, 100, 327-31. DOI ScienceOn |
18 | Madersbacher S, Marszalek M, Lackner J, et al (2007). The long-term outcome of medical therapy for BPH. Eur Urol, 51, 1522-33. DOI ScienceOn |
19 | McVary KT (2006). BPH: epidemiology and comorbidities. Am J Manag Care, 12, S122-8. |
20 | Michel MC, Vrydag W (2006). Alpha1-, alpha2- and betaadrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol, 147, 88-119. DOI |
21 | Nunez J, Nunez E, Bodi V, et al (2008). Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am J Cardiol, 101, 747-52. DOI ScienceOn |
22 | Ozden C, Ozdal OL, Guzel O, et al (2007). The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis. Int Urol Nephrol, 39, 859-63. DOI ScienceOn |
23 | Partin AW, Carter HB, Chan DW, et al (1990). Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol, 143, 747-52. |
24 | Roehrborn CG (2008). BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int, 101, 17-21. |
25 | Roehrborn CG, Boyle P, Bergner D, et al (1999). Serum prostatespecific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology, 54, 662-9. DOI |
26 | Tamhane UU, Aneja S, Montgomery D, et al (2008). Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol, 102, 653-7. DOI ScienceOn |
27 | Sebastiano C, Vincenzo F, Tommaso C, et al (2012). Dietary patterns and prostatic diseases. Front Biosci, 4, 195-204. |
28 | SpringerBasicRoehrborn CG, Barkin J, Tubaro A, et al (2014). Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. BJU Int, 113, 623-35. DOI |
29 | St Sauver JL, Jacobson DJ, McGree ME, et al (2008). Longitudinal association between prostatitis and development of benign prostatic hyperplasia. Urology, 71, 475-9; discussion 9. DOI |
30 | Walsh SR, Cook EJ, Goulder F, et al (2005). Neutrophillymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol, 91, 181-4. DOI ScienceOn |
31 | Cihan YB, Arslan A, Ergul MA (2013). Subtypes of white blood cells in patients with prostate cancer or benign prostatic hyperplasia and healthy individuals. Asian Pac J Cancer Prev, 14, 4779-83. 과학기술학회마을 DOI ScienceOn |